Approved by the National Medical Products Administration for the Marketing of Didacinib Capsules
* Source: * Author: admin * Publication time: 2022/05/30 9:39:50 * Browse: 57
Recently, the National Medical Products Administration approved the listing of the Class 1 innovative drug, Dacinib capsules, applied by Zhejiang Jingxin Pharmaceutical Co., Ltd. This medicine is suitable for short-term treatment of patients with insomnia disorders.
Didaxinib belongs to the benzodiazepine class of drugs and is γ- Partial positive allosteric modulators of aminobutyric acid type A (GABAA) receptors produce sleep promoting effects by partially activating GABAA receptors. The launch of this drug provides a new treatment option for patients with insomnia disorders.
其他新闻
-
-
Top economists call for radical redirection of the economy to put Health for All at the centre in the run-up to G20
-
Approved by the National Medical Products Administration for the Marketing of Didacinib Capsules
-
New ACT-Accelerator strategy calls for US$ 23.4 billion international in for COVID-19 vaccines, tests & treatmentsvestment